AllDocs -> cancers

prostate cancer 1 2/17/05 VISION Eliminate PCa as a cause of death and of suffering for men and their families MISSION To make PCa an urgent priority within Virginia through education, outreach, advocacy and fundraising programs Virginia Prostate Cancer Coalition (VPCC) Making Prostate Cancer History in Virginia! © 2/17/05 2 Virginia Prostate Cancer Coalition (VPCC) Making Prostate Cancer History in Virginia! © GOALS Increase coalition participation Identify major funding sources Legislative liaison (State & Federal) Increase PCa research funding Increase public awareness and visibility of PCa 2/17/05 3 GOALS (cont.) ...

Prostate Cancer : Causes, Diagnosis and Treatment Options PN 871083 Rev. B 10/05 Page 1 of 4 Prostate Cancer : Causes, Diagnosis and Treatment Options Causes of Prostate Cancer While the causes of prostate cancer are largely unknown, it is clear that the chance of developing prostate cancer increases in men over 50. Close relatives of men who have had prostate cancer are also more likely to be affected. Ethnic origin appears to play a part: Men of African heritage are at highest risk, and men of Far-Eastern descent have the lowest risk of developing prostate cancer . It may be possible to reduce the risk by following a low-fat diet and staying in shape. For example, men may reduce their risk through daily exercise and by cutting back on foods high in animal fat. Diagnosis Testing a blood sample for the level of Prostate Specific Antigen (PSA) plays an important part in the ...

National Prostate Cancer Conference Forward Together: Getting the Best for Men Research – Hope or Hype? Professor Norman Maitland Page 2 Just what is research? • Basic Research • Paraclinical / Translational Research • Clinical (Patient Trial) Research Page 3 Hype: Media or investigator driven? ££ £ £££££££££££££££ t=0 t=5 t=10 Looks like your PSA has gone down Looks like your PSA has gone down Research Grant Pre-clinical Testing Clinical Trials The idea! The Patient! Page 4 Is there hope? Page 5 A real reality check from the use of Herceptin in Breast Cancer Page ...

PRACTICE GUIDELINE – page 1 Evidence-based Series #3-15: Section 1 Non-Hormonal Systemic Therapy in Men with Metastatic Hormone- Refractory Prostate Cancer : A Clinical Practice Guideline E. Winquist, T. Waldron, S. Berry, D.S. Ernst, S. Hotte, H. Lukka, and members of the Genitourinary Cancer Disease Site Group A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Developed by the Genitourinary Cancer Disease Site Group Report Date: November 1, 2005 Question Which non-hormonal systemic therapies are most beneficial and should be recommended for the treatment of hormone-refractory prostate cancer ? First-line cytotoxic and non-cytotoxic systemic therapies are the agents of interest. Overall survival, disease control (as assessed by measures such as progression-free survival, time-to-progression, time-to-treatment ...

Cancer Control November 2005 116 Cancer , Culture and Literacy Supplement Prostate Cancer Screening in a Low-Literacy Population: Does Informed Decision Making Occur? Sunil Kripalani, MD, MSc, Jyoti Sharma, BA, Elizabeth Justice, BA, Jeb Justice, BA, Cynthia Spiker, MPH, Larry E. Laufman, PhD, Terry A. Jacobson, MD, and Armin D. Weinberg, PhD Introduction Although prostate cancer is the most common non–skin- related cancer among American men,screening for prostate cancer remains controversial. 1-5 The US Preventive Services Task Force and several professional organizations recom- mend that physicians counsel their patients on the risks and benefits of prostate cancer screening so that patients may make an informed decision about testing. 2,6 Experts sug- gest that such counseling include the uncertain value ...

Long-term ClinicalOutcomes of 420 Consecutive Prostate Cancer Patients in a Single Institute Kohei Edamura, Takashi Saika , Takashi Senoh, Fumihito Koizumi, DaisukeManabe, Shin Ebara, Haruki Kaku, Teruhiko Yokoyama, Fernando Abarzua, Atsushi Nagai, Yasutomo Nasu, Tomoyasu Tsushima, and Hiromi Kumon Department of Urology, Okayama UniversityGraduateSchool of Medicineand Dentistry, Okayama 700-8558, Japan This studywas undertaken to reveal the trends of prostate cancer and the outcome of treatment modalitiesforeach diseasestagein patientsin asingleinstituteovera10-yearperiod. FromJanuary 1994through December 2003, 420consecutivepatients with previouslyuntreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer -specific survival, and prostate ...

PROSTATE CANCER IN IDAHO 1971-1998 • Incidence • Risk Factors • Screening • Staging • Treatment • Survival • Mortality • Lifetime Risks This pamphlet includes information on prostate cancer : Page 2 DEFINITIONS ACS: American Cancer Society Age-adjustment: a technique which permits comparison of incidence or mortality rates after removing the effect of differing age distributions among the compared population groups. An age-adjusted rate is the hypothetical rate that would be observed in a population group if the age distribution of the group were the same as the age distribution of the standard population. BRFSS: the Behavioral Risk Factor Surveillance System is an ongoing surveillance program developed by the Centers for Disease Control and Prevention. It is designed to estimate the prevalence ...

For more information you can contact: ? Your doctor ? NHS Direct: 0845 4647 www.nhsdirect.nhs.uk ? The Prostate Cancer Charity 0845 300 8383 (confidential helpline) www. prostate - cancer .org.uk African Caribbean men have higher rates of prostate cancer . They are more than three times as likely to be diagnosed with prostate cancer than white men. Prostate Cancer Information for African Caribbean men Designed @ Liv erpool Health Pr omotion Ser vice Design S t udio 200 4 • www .lhps.org.uk Page 2 Causes and prevention Developing prostate cancer becomes more likely as you get older. A diet high in animal fat will also increase your risk. If you have a close family member who has ...

prostate cancer PROnet – a Global Alliance of Prostate Cancer Patient Organisations Background Information What is PROnet? PROnet is a new global network of organisations working with men living with Prostate Cancer , their partners, families and friends. The network, established in 2000, was formed in order to share information and best practice about Prostate Cancer awareness, early detection, treatment, support and services. PROnet aims To identify best practice and to enable organisations to use shared experience as a resource for developing their own services To provide technical assistance and support to countries developing new prostate cancer groups and to emerging patient organisations PROnet goals To raise global awareness of Prostate Cancer and its risk factors To publicise the availability of early detection methods, treatment ...

NHC adviser An “accessible” version of the NHC adviser and all NHC and PHAC reports are available at www.nhc.govt.nz Incorporating the Public Health Advisory Committee Te Ropu Tohutohu i te Hauora Tumatanui No not yet for prostate cancer screening The National Health Committee has recommended for the second time that prostate cancer screening should not be introduced in New Zealand. In a report to the Minister of Health in April, ‘ Prostate Cancer Screening in New Zealand,’ the NHC found no conclusive evidence that the currently available screening test for prostate cancer , the Prostate Specific Antigen – or PSA test, will reduce deaths associated with prostate cancer , that the test is not completely reliable and that it can miss some cancers. In summary, the test may offer little benefit and has the potential to cause harm. ...

Prostate Cancer Staging and Grading What is cancer grading? Grading is used to describe how abnormal or aggressive the cancer cells appear. The grade helps to estimate long-term results, how a tumor may respond to treatment and the overall survival rates. What is the Gleason score? The Gleason scale is the most common scale used for grading prostate cancer . This scale gives cancer cells a score from 1 to 10. The grades of the two most common patterns of cells found within the tumor are added together to give a total score. For example cells with grades of 3 + 4 = a total grade of 7. Gleason scores generally range between 4 and, most commonly, 6 or 7. These scores are then grouped into three main levels: C Low-grade (well differentiated): This type of slow-growing cancer looks the most like normal prostate cells and is the least dangerous. It has a Gleason ...

Prostate Cancer Screening Position Statement The Cancer Council Australia Background The prostate is a gland found only in men. It sits just below the bladder and surrounds the urethra. The prostate gland produces a fluid that forms part of the semen. Impact (prevalence, incidence, mortality) Prostate cancer is the most commonly diagnosed cancer in Australian men (apart from non-melanoma skin cancers) and is the second-leading cause of cancer death in Australian men 1 . It is estimated that there are over 61,000 Australian men currently living who have had a diagnosis of prostate cancer . 2 In 2001, 11,191 men were diagnosed with the disease. In the same year, 2718 men died from the disease. Risk factors Increasing age is the most significant risk factor for prostate cancer . Prostate cancer affects mostly men in older ...

prostate cancer 1186 Women Join the TEAM Approach to Prostate Cancer Treatment --> The TEAM Approach It’s a TEAM Approach: Prostate Cancer T reatment, E ducation, A wareness and M anagement is a national awareness campaign that aims to make men with prostate cancer aware of the importance of seeking advice from a multidisciplinary team of physicians—a urologist, a radiation oncologist, and a medical oncologist— to ensure that all available treatment options are fully explored so that an optimal treatment plan can be implemented. The Influence of Women as Caregivers and Their Ability to Help Men with Prostate Cancer Traditionally, women tend to be the primary ...

Contact Andrew Bright +1 (484) 530 3922 andrew.bright@oncura.com www.oncura.com ONCURA™ Announces French Reimbursement for Their Leading Prostate Cancer Treatment Products. Paris, June 7th, 2005 - ONCURA, a global leader in the minimally invasive management of prostate cancer announces the recent establishment of reimbursement in France for its prostate brachytherapy products; RAPID Strand™, EchoSeed™ and OncoSeed™. Prostate brachytherapy consists of the permanent placement of radioactive seeds in the prostate . The seeds are about the size of a grain of rice and once in the prostate provide therapeutic radiation to treat the cancer , with minimal impact on surrounding parts of the body. This is unlike other treatment options such as external radiation, where the prostate and surrounding tissue receive multiple radiation treatments from different directions, ...

CONTACT: Andrew Bright + 1 (484) 530 3922 andrew.bright@oncura.com www.oncura.com ONCURA™ introduces innovations in prostate cancer cryotherapy at the annual meeting of the American Urological Association Philadelphia (May 19, 2004) — As the global leader in minimally invasive prostate cancer treatment ONCURA has an extensive product development program dedicated to improving quality of life for the many men who require treatment each year. At this month’s annual meeting of the American Urological Association (AUA) in San Francisco, ONCURA introduced innovations that will increase the utility of their unique 17 gauge CryoNeedle™ technology. These innovations included an increase in the size of the therapeutic ice ball generated by their 17 gauge CryoNeedle, various other enhancements that are designed to decrease the time a patient is required to spend in the operating ...

VOLUME 1 ISSUE 1 WI NTER 2002 Prostate Cancer : The Next River To Cross The African American community has experienced many burdens, including higher rates of prostate cancer . Black men are twice as likely to die from prostate cancer as any other group of men. I believe that some things should not have to pass from generation to generation. Genetics is an area that holds tremendous promise for men with prostate cancer . As a prostate cancer survivor, I want to help all African Ameri- can men have the ability to live and enjoy their children and grandchildren! That is why I became involved with and en- couraged other urologists to be part of the African American Hereditary Prostate Cancer Study. - Isaac Powell, M.D., Pros- tate Cancer Survivor and Principal Investigator, AAHPC ...

119 10. Screening for Prostate Cancer Burden of Suffering Prostate cancer is the most common noncutaneous cancer in American men. 1 After lung cancer , it accounts for more cancer deaths in men than any other single cancer site. Prostate cancer accounted for an estimated 244,000 new cases and 40,400 deaths in the U.S. in 1995. 1 Risk increases with age, beginning at age 50, and is also higher among African American men. Because it is more common in older men, prostate cancer ranks 21st among cancers in years of potential life lost. 2 The age-adjusted death rate from prostate cancer increased by over 20% between 1973 and 1991. 3 The lifetime risk of dying from prostate cancer is 3.4% for American men. 3 The reported incidence of prostate cancer has increased in recent years by 6% ...

Incidence and Mortality Rate Trends Prostate cancer is the most common cancer , excluding skin cancer , and the second leading cause of cancer -related death in men in the United States. Over time, African American men have had higher incidence and at least double the mortality rates compared to men of other racial and ethnic groups. Prostate cancer incidence rates rose dramatically in the late 1980s. This increase reflects improvements in detection and diagnosis through widespread use of prostate -specific antigen (PSA) testing, which received initial Food and Drug Administration approval in 1986. In the early 1990s, prostate cancer incidence began declining and has leveled off in recent years. Mortality rates for prostate cancer have declined since the early 1990s. It is estimated that approximately $8 billion* is spent on prostate ...

1 Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data Lei Xu 1 , Aik Choon Tan 1 , Daniel Q. Naiman 1,2 , Donald Geman 1,2 and Raimond L. Winslow 1 1 The Whitaker Biomedical Engineering Institute and Center for Cardiovascular Bioinformatics and Modeling 2 Department of Applied Mathematics and Statistics and Center for Imaging Sciences The Johns Hopkins University, Baltimore MD 21218 USA ABSTRACT Motivation: DNA Microarray data analysis has been used previously to identify marker genes which discriminate cancer from normal samples. However, due to the limited sample size of each study, there are few common markers among different studies of the same cancer . With the rapid accumulation of microarray data, it is of great interest to ...

FOR IMMEDIATE RELEASE Contact: Meghan Wedd McGuire 803-737-2325 healthysc@gov.sc.gov September is National Prostate Cancer Month Did you know one out of every six American men will get prostate cancer during his lifetime? In fact, prostate cancer is the second leading cause of cancer death in U.S. men, and South Carolina’s rates of prostate cancer deaths are the third highest in the county. The SC Cancer Alliance has graded our state F for number of prostate cancer diagnoses, and F for prostate cancer deaths. As well, the health disparities in our state are quite alarming - African-American males are three times more likely to die of prostate cancer than white males. By the end of 2005, 4,210 men in our state will have developed prostate cancer and about 550 will die of this mostly preventable disease. What can you do? First of all, know ...

What You Should Know About Prostate Cancer T he Prostate Cancer Foundation is dedicated to finding better treatments and a cure for recurrent prostate cancer . Since inception in 1993, the Prostate Cancer Foundation (PCF) has become the world’s largest philanthropic source of support for prostate cancer research. As the largest source of private funding for prostate cancer research in the world, the Prostate Cancer Foundation has awarded more than $208 million to help fund over 1,100 research projects in more than 100 major academic medical centers worldwide in the past ten years.These researchers are investigating every option, including vaccines, gene therapy, signal transduction, apoptosis, nutrition, and other approaches. Today, the Prostate Cancer Foundation is sharpening its focus to accelerate the movement of research from the lab to patients. Having sparked interest ...

The PSA Test for Prostate Cancer What is the prostate gland? The prostate gland (just called ' prostate ' from now on) is only found in men. It lies just beneath the bladder (see diagram). It is normally about the size of a chestnut. The urethra (the tube which passes urine from the bladder) runs through the middle of the prostate . The prostate helps to make semen, but most semen is made by the seminal vesicle (another gland nearby). The most common problem of the prostate is prostate enlargement (also called Benign Prostatic Hyperplasia). This is a benign (non-cancerous) condition where the prostate gets bigger ('enlarges') gradually after the age of about 50. By the age of 70, about 8 in 10 men have an enlarged prostate . This condition can cause symptoms such as passing urine frequently, difficulty in passing urine, etc. A separate leaflet gives more ...

SEER Program 41 National Cancer Institute SURVIVAL The fact that one of the treatment options for some men is no treatment or “watchful waiting” (a delay in active treatment) suggests that the expected number of years of life remaining without treatment is equal to or greater than that with treatment. Given that a man may survive for many years after a diagnosis of prostate cancer , information on survival probabilities can play an important role in planning treatment strategies. In addition, differences in survival between defined subgroups of patients allow clinicians and policy makers to better target interventions. One way to describe the survival experience of a cohort of patients over an extended period of time is the five-year survival rate. This value is simply the cumulative proportion of patients surviving at the end of the fifth year ...

The Marie Keating Foundation has been established to provide cancer information and awareness free of charge to the general public throughout Ireland. Our Mobile Units carry information on Breast, Testicular, Prostate , Bowel, Lung, Skin, Ovarian and Cervical cancer . Our service is provided through our registered Nurses on board the Units, leaflet information, teaching aids, presentations, exhibitions and seminars. The Marie Keating Foundation offers Medical and Nursing Scholarships. Our future projects include Marie Keating Foundation waiting rooms within Cancer Care Hospitals. As the Marie Keating Foundation is not government funded we depend on private and corporate donations. We at the Marie Keating Foundation would like to thank Breast Check, The Irish Cancer Society, Action Cancer Northern Ireland, Cancer Research UK and health care professionals specializing in cancer ...

Store-operated Ca 2 Current in Prostate Cancer Epithelial Cells ROLE OF ENDOGENOUS Ca 2 TRANSPORTER TYPE 1* Received for publication, November 27, 2002, and in revised form, February 5, 2003 Published, JBC Papers in Press, February 12, 2003, DOI 10.1074/jbc.M212106200 Fabien Vanden Abeele‡, Morad Roudbaraki‡, Yaroslav Shuba§, Roman Skryma, and Natalia Prevarskaya ¶ From the Laboratoire de Physiologie Cellulaire, INSERM EMI 0228, Bâtiment SN3, USTL, 59655 Villeneuve d’Ascq, France Ca 2 influx via store-operated channels (SOCs) follow- ing stimulation of the plasma membrane receptors is the key event controlling numerous processes in nonexcit- able cells. The human transient receptor potential va- nilloid type 6 channel, originally termed Ca 2 trans- porter type 1 (CaT1) protein, ...

MDS Diagnostic Services 100 International Blvd. Toronto, Ontario Canada M9W 6J6 www.mdsdx.com PSARFAL03E L e a r n M o r e A b o u t L e a r n M o r e A b o u t L A B T E S T S www.mdsdx.com Prostate Cancer P S A R a t i o Te s t i n g a n d Page 2 What’s Inside In this leaflet you will learn about a simple blood test, called the Prostate -Specific Antigen Ratio (PSA Ratio) test. This test is also referred to as a Free PSA. Managing your Health Your healthcare provider uses a variety of tests to determine your current health status. Some of these tests are performed on an annual basis and some are ordered when specific symptoms require a closer look. All of the information gained through these tests allows you and your doctor to work together, as a team, to best manage your overall ...

A systematic review of prostate cancer biopsy schemes Prostate Cancer Biopsy Schemes ¦ Prostate cancer is the second leading cause of male cancer death in Europe and North America. ¦ Generally, men with raised PSA levels or abnormal rectal digital examination undergo ultrasound guided transrectal needle biopsy to obtain samples of prostate for diagnosis. ¦ The sextant biopsy scheme has been standard for many years, however a number of more extended prostate biopsy schemes are now being used in practice. ¦ The sextant scheme showed a significantly lower cancer yield than most of the more extensive biopsy schemes. ¦ The addition of laterally directed cores from the lateral peripheral zone to the mid lobe peripheral zone increases ...

Ending the Threat of Prostate Cancer PROGRESS REPORT ON PROSTATE CANCER RESEARCH November 2002 Page 2 Ending the Threat of Prostate Cancer PROGRESS REPORT ON PROSTATE CANCER RESEARCH TABLE OF CONTENTS Part I Prostate Cancer : Ending the Threat Introduction 1 The Prostate and Prostate Cancer 1 Epidemiology 1 Symptoms 2 Risk Factors 3 Prevention 4 Early Detection 5 Treatment Options 6 Funding for Prostate Cancer Research 7 Research Funded by the Prostate Cancer 7 Research Foundation of Canada Part II Defeating Prostate Cancer : A Research Survey Introduction 11 Early Detection, Diagnosis and Prognosis 12 Biology, Progression and Metastasis 12 Genetic Origins of Prostate Cancer 13 ...

A 614 VOLUME 113 | NUMBER 9 | September 2005 • Environmental Health Perspectives Environews Science Selections Brand X Rocking the Cradle Phthalate Exposure in NICU Infants Animal studies have linked di(2-ethylhexyl) phthalate (DEHP) with reproductive and developmental toxicity, and have demonstrated an especially pronounced effect on testicular development when administered postnatal- ly. Previous research has shown that newborns treated at neonatal intensive care units (NICUs) may receive doses of DEHP at 2–3 times the average daily adult exposure, and that these infants have relatively high urinary levels of the DEHP metabolite mono(2-ethylhexyl) phthalate (MEHP). Now researchers, using urinary MEHP as a biomarker of DEHP exposure, demonstrate for the first time that the more DEHP-containing devices are used in ...